Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.63 |
| ▸ | NPC1 | O15118 | 11/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.58 |
| ▸ | RELA | Q04206 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.48 |
| ▸ | GAA | P10253 | 5/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 9/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218108 | 0.89 | SMN1; SMN2 (0.59) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL218801 | 0.83 | NR4A2 (0.51) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL219537 | 0.82 | NR4A2 (0.49) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL219242 | 0.81 | ALDH1A3 (0.54) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL219360 | 0.81 | NPC1 (0.57) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL218240 | 0.81 | ALDH1A1 (0.57) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL217629 | 0.79 | ALDH1A1 (0.61) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL220707 | 0.78 | ALDH1A1 (0.55) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL219685 | 0.78 | NR4A2 (0.40) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL219842 | 0.78 | NR4A2 (0.45) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262804-B1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-12-03 | — | — | EP | claimed |
| US-8598166-B2 | Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI (FR) | 2013-12-03 | — | — | US | claimed |
| US-8088765-B2 | Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | claimed |
| US-20110065700-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | claimed |
| EP-2262804-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-aventis (FR) | 2010-12-22 | — | — | EP | claimed |
| WO-2009144392-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | WO | claimed |
| EP-2262804-B1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-12-03 | — | — | EP | disclosed |
| US-8598166-B2 | Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI (FR) | 2013-12-03 | — | — | US | disclosed |
| US-20120053202-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-01 | — | — | US | disclosed |
| US-8088765-B2 | Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |
| US-20110065700-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
| EP-2262804-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-aventis (FR) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009144392-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065700-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | CYP4X1, HAX1, JAK2 | RAB9A 1592/4885NPC1 1704/4885SMN1; SMN2 3292/4885 |
| US-20120053202-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | CYP4X1, HAX1, JAK2 | RAB9A 1592/4885NPC1 1704/4885SMN1; SMN2 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.